Friday, July 24, 2015
Tekmira Pharmaceuticals, headquartered in Vancouver, Canada, plans to change its corporate name to Arbutus Biopharma, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before Aug. 3. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields a large portfolio of HBV product candidates in the industry.
Eli Lilly has inked two separate deals, one with the Dana-Farber Cancer Institute to research new medicines under development to fight cancer, and the second with the Sarah Cannon Research Institute (SCRI) to co-develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor.
The Society for Clinical Research Sites (SCRS), a global trade organization fully dedicated to representing the interests of clinical research sites, has announced a program for the 2015 Asia-Pac Site Solutions Summit. The Asia-Pac Site Solutions Summit will be July 30-31, 2015 in Melbourne, Australia. The Summit is open to clinical research investigators, site executives and industry stakeholders.
A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.
Eli Lilly and Sanford-Burnham Medical Research Institute, a nonprofit medical research institute based in Florida, are collaborating to discover and develop immunological therapies. The company will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren’s Syndrome, inflammatory bowel disease and other autoimmune disorders.
Eli Lilly and Biopharmaceutical New Technologies (BioNTech), a Germany-based immunotherapy company, have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients.